Reply to: Moyamoya disease and systemic sclerosis (MoSys syndrome): a combination of two rare entities - comment to the authors

Sirs,

We greatly thank de Langhe et al. for their comment on our article “Moyamoya disease and systemic sclerosis (MoSys syndrome): a combination of two rare entities (1, 2). By observing the rare combination of Moyamoya-disease (MMD) and diffuse cutaneous systemic sclerosis (SSc) in another patient, we feel supported in our hypothesis that the vascular changes described in MMD could indeed reflect cerebral manifestations of SSc in these patients (MoSys-syndrome). Currently, there are only a few studies investigating the risk of stroke in SSc patients (3, 4). To our knowledge, systematic cohort analysis and retrospective studies evaluating the involvement of cerebral vessels and/or manifestations in SSc patients are missing. In our opinion, systematic analysis of cerebral manifestations in SSc are warranted by the observations made in these patients and could possibly discover a yet neglected comorbidity, again proving the multifaceted character of SSc.

F. Wegner, MD
U. Müller-Ladner, MD
F.M.P. Meier, MD
Department of Internal Medicine and Rheumatology, Justus-Liebig-University, Giessen, and Kerckhoff-Klinik, Bad Nauheim, Germany.

Please address correspondence to:
Prof. Ulf Müller-Ladner, Department of Rheumatology, University of Giessen, Kerckhoff Clinic, Benekestrasse 2-8, 61231 Bad Nauheim (Hessen), Germany.
E-mail: u.mueller-ladner@kerckhoff-klinik.de
Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2017.

References